BACKGROUND: Previous studies have suggested that azithromycin improves lung function in lung transplant recipients with bronchiolitis obliterans syndrome (BOS). However, these studies did not include a non-treated BOS control cohort or perform survival analysis. This study was undertaken to estimate the effect of azithromycin treatment on survival in lung transplant recipients with BOS. METHODS: We conducted a retrospective cohort study of consecutive lung transplant recipients who developed BOS between 1999 and 2007. An association between azithromycin treatment and death was assessed using univariate and multivariate time-dependent Cox regression analysis. RESULTS: Of the 178 recipients who developed BOS in our study, 78 did so after 2003 and were treated with azithromycin. The azithromycin-treated and untreated cohorts had similar baseline characteristics. Univariate analysis demonstrated that azithromycin treatment was associated with a survival advantage and this beneficial treatment effect was more pronounced when treatment was initiated during BOS Stage 1. Multivariate analysis demonstrated azithromycin treatment during BOS Stage 1 (adjusted hazard ratio = 0.23, p = 0.01) and absolute forced expiratory volume in 1 second (FEV(1)) at the time of BOS Stage 1 (adjusted hazard ratio = 0.52, p = 0.003) were both associated with a decreased risk of death. CONCLUSIONS: In lung transplant recipients with BOS Stage 1, azithromycin treatment initiated before BOS Stage 2 was independently associated with a significant reduction in the risk of death. This finding supports the need for a randomized, controlled trial to confirm the impact of azithromycin on survival in lung transplant recipients. Copyright (c) 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
BACKGROUND: Previous studies have suggested that azithromycin improves lung function in lung transplant recipients with bronchiolitis obliterans syndrome (BOS). However, these studies did not include a non-treated BOS control cohort or perform survival analysis. This study was undertaken to estimate the effect of azithromycin treatment on survival in lung transplant recipients with BOS. METHODS: We conducted a retrospective cohort study of consecutive lung transplant recipients who developed BOS between 1999 and 2007. An association between azithromycin treatment and death was assessed using univariate and multivariate time-dependent Cox regression analysis. RESULTS: Of the 178 recipients who developed BOS in our study, 78 did so after 2003 and were treated with azithromycin. The azithromycin-treated and untreated cohorts had similar baseline characteristics. Univariate analysis demonstrated that azithromycin treatment was associated with a survival advantage and this beneficial treatment effect was more pronounced when treatment was initiated during BOS Stage 1. Multivariate analysis demonstrated azithromycin treatment during BOS Stage 1 (adjusted hazard ratio = 0.23, p = 0.01) and absolute forced expiratory volume in 1 second (FEV(1)) at the time of BOS Stage 1 (adjusted hazard ratio = 0.52, p = 0.003) were both associated with a decreased risk of death. CONCLUSIONS: In lung transplant recipients with BOS Stage 1, azithromycin treatment initiated before BOS Stage 2 was independently associated with a significant reduction in the risk of death. This finding supports the need for a randomized, controlled trial to confirm the impact of azithromycin on survival in lung transplant recipients. Copyright (c) 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: A Elssner; F Jaumann; S Dobmann; J Behr; M Schwaiblmair; H Reichenspurner; H Fürst; J Briegel; C Vogelmeier Journal: Transplantation Date: 2000-07-27 Impact factor: 4.939
Authors: G C Riise; B A Andersson; C Kjellström; G Martensson; F N Nilsson; W Ryd; H Scherstén Journal: Eur Respir J Date: 1999-11 Impact factor: 16.671
Authors: Jason D Christie; Leah B Edwards; Paul Aurora; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; David O Taylor; Anna Y Kucheryavaya; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2008-09 Impact factor: 10.247
Authors: Susan G Gerhardt; John F McDyer; Reda E Girgis; John V Conte; Stephen C Yang; Jonathan B Orens Journal: Am J Respir Crit Care Med Date: 2003-04-02 Impact factor: 21.405
Authors: R Duane Davis; Christine L Lau; Steve Eubanks; Robert H Messier; Denis Hadjiliadis; Mark P Steele; Scott M Palmer Journal: J Thorac Cardiovasc Surg Date: 2003-03 Impact factor: 5.209
Authors: E A Lendermon; J M Dodd-O; T A Coon; X Wang; C R Ensor; N Cardenes; C L Koodray; H L Heusey; M F Bennewitz; P Sundd; G C Bullock; I Popescu; L Guo; C P O'Donnell; M Rojas; J F McDyer Journal: Transplant Proc Date: 2018-03-09 Impact factor: 1.066
Authors: Emily S Charlson; Joshua M Diamond; Kyle Bittinger; Ayannah S Fitzgerald; Anjana Yadav; Andrew R Haas; Frederic D Bushman; Ronald G Collman Journal: Am J Respir Crit Care Med Date: 2012-07-12 Impact factor: 21.405
Authors: P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis Journal: Eur J Clin Pharmacol Date: 2011-11-22 Impact factor: 2.953
Authors: Aric L Gregson; Xiaoyan Wang; S Sam Weigt; Vyacheslav Palchevskiy; Joseph P Lynch; David J Ross; Bernard M Kubak; Rajan Saggar; Michael C Fishbein; Abbas Ardehali; Gang Li; Robert Elashoff; John A Belperio Journal: Am J Respir Crit Care Med Date: 2013-01-17 Impact factor: 21.405